The PBM industry has developed a rich vocabulary for making harmful practices sound like services. Below is a plain-English translation of the terms you’ll encounter — and what they actually mean for your wallet and your health.
Glossary of bullsh*t
Spread pricing
DIR fees
Formulary
Rebate retention
Step therapy
Prior authorization
Vertical integration
Gag clause
Spread pricing
What they call it: A standard reimbursement mechanism.
What it actually is: The PBM bills your employer's health plan one amount for a drug and pays the pharmacy a lower amount — keeping the difference as profit. The "spread" can be substantial. Ohio's Medicaid program found PBMs overcharged the state by $224 million through this practice in a single year.
DIR fees
What they call it: Direct and Indirect Remuneration — a performance-based quality adjustment.
What it actually is: Fees clawed back from pharmacies months after a prescription was filled. The pharmacy has no way to know at the point of dispensing what its true reimbursement will be. Pharmacies operating on thin margins have been driven out of business by retroactive DIR fees they couldn't anticipate or plan for.
Formulary
What they call it: A list of covered medications selected for clinical effectiveness and value.
What it actually is: A list of drugs the PBM has chosen to cover, heavily influenced by which manufacturers pay the largest rebates for preferred placement. A drug may be clinically superior and cost less — and still be on a worse tier, or excluded entirely, because it generates less revenue for the PBM.
Rebate retention
What they call it: Manufacturer rebates — savings passed to plan sponsors.
What it actually is: PBMs negotiate rebates from drug manufacturers in exchange for formulary placement. A portion — sometimes the majority — is retained by the PBM rather than passed through to the health plan or the patient. These retained rebates are a primary profit center for large PBMs and a primary reason drug list prices stay artificially high.
Step therapy
What they call it: A clinically sound protocol requiring patients to try lower-cost treatments first.
What it actually is: A coverage requirement that forces patients to try — and fail on — one or more cheaper drugs before the PBM will authorize the drug their doctor actually prescribed. In many cases the "required" first-step drug is one that generates more rebate revenue for the PBM, not one that is clinically preferred for the patient.
Prior authorization
What they call it: A utilization management tool to ensure appropriate, evidence-based prescribing.
What it actually is: A bureaucratic hurdle that requires a doctor to obtain PBM approval before a prescription can be filled. The process can take days or weeks. Patients sometimes go without medication while waiting. Physicians report spending significant time on prior authorization paperwork that contributes nothing to patient care.
Vertical integration
What they call it: A comprehensive, coordinated care model offering efficiencies across the health system.
What it actually is: The Big 3 PBMs each own the health insurer that steers patients to them, the mail-order pharmacy that fills the prescriptions, and the specialty pharmacy that handles high-cost drugs. This means a single company controls whether your drug is covered, where you fill it, and how much the pharmacy gets paid — with every decision influenced by what maximizes profit for the enterprise, not what is best for the patient.
Gag clause
What they called it: A standard contractual confidentiality provision.
What it actually was: A contractual prohibition preventing pharmacists from telling you when the cash price of your medication was lower than your copay. Your pharmacist knew. They weren't allowed to say. Congress banned new gag clauses in 2018. The damage done in the years before that ban — patients overpaying at the counter while their pharmacist stayed silent by contract — is not undone by the legislation.